EE05110B1 - 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning - Google Patents

3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning

Info

Publication number
EE05110B1
EE05110B1 EEP200200656A EEP200200656A EE05110B1 EE 05110 B1 EE05110 B1 EE 05110B1 EE P200200656 A EEP200200656 A EE P200200656A EE P200200656 A EEP200200656 A EE P200200656A EE 05110 B1 EE05110 B1 EE 05110B1
Authority
EE
Estonia
Prior art keywords
derivatives
preparation
azabicyclo
exo
triazol
Prior art date
Application number
EEP200200656A
Other languages
English (en)
Estonian (et)
Inventor
Perros Manoussos
Anthony Price David
Luzia Christa Stammen Blanda
Wood Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200200656A publication Critical patent/EE200200656A/xx
Publication of EE05110B1 publication Critical patent/EE05110B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
EEP200200656A 2000-05-26 2001-05-09 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning EE05110B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
PCT/IB2001/000806 WO2001090106A2 (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators

Publications (2)

Publication Number Publication Date
EE200200656A EE200200656A (et) 2004-06-15
EE05110B1 true EE05110B1 (et) 2008-12-15

Family

ID=26244452

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200656A EE05110B1 (et) 2000-05-26 2001-05-09 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning

Country Status (50)

Country Link
EP (3) EP1990341B1 (online.php)
JP (2) JP3693957B2 (online.php)
KR (2) KR100548854B1 (online.php)
CN (2) CN1279040C (online.php)
AP (1) AP1965A (online.php)
AR (2) AR028622A1 (online.php)
AT (2) ATE260914T1 (online.php)
AU (2) AU2001252482B2 (online.php)
BG (1) BG65966B1 (online.php)
BR (1) BRPI0110955B8 (online.php)
CA (1) CA2408909C (online.php)
CR (1) CR10145A (online.php)
CU (1) CU23288B7 (online.php)
CY (3) CY2008006I2 (online.php)
CZ (1) CZ299102B6 (online.php)
DE (3) DE60135685D1 (online.php)
DK (2) DK1284974T3 (online.php)
DZ (1) DZ3464A1 (online.php)
EA (2) EA005382B1 (online.php)
EE (1) EE05110B1 (online.php)
EG (1) EG24137A (online.php)
ES (3) ES2401812T3 (online.php)
FR (1) FR08C0007I2 (online.php)
GE (1) GEP20063799B (online.php)
HR (1) HRP20020938B1 (online.php)
HU (1) HU225810B1 (online.php)
IL (2) IL152531A0 (online.php)
IS (1) IS2511B (online.php)
LT (1) LTC1284974I2 (online.php)
LU (1) LU91417I2 (online.php)
MA (1) MA26902A1 (online.php)
ME (1) ME00555A (online.php)
MX (1) MXPA02011631A (online.php)
MY (3) MY156920A (online.php)
NL (1) NL300338I2 (online.php)
NO (3) NO327892B1 (online.php)
NZ (1) NZ521477A (online.php)
OA (1) OA12264A (online.php)
PA (1) PA8517101A1 (online.php)
PE (1) PE20011371A1 (online.php)
PL (1) PL200551B1 (online.php)
PT (2) PT1526134E (online.php)
RS (2) RS50904B (online.php)
SI (2) SI1526134T1 (online.php)
SK (1) SK286129B6 (online.php)
TN (1) TNSN01077A1 (online.php)
TR (1) TR200400541T4 (online.php)
TW (1) TWI230160B (online.php)
UY (1) UY26727A1 (online.php)
WO (1) WO2001090106A2 (online.php)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy
CA2450271A1 (en) * 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
RS51550B (sr) * 2002-04-08 2011-06-30 Pfizer Inc. Derivati tropana kao modulatori ccr5
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
ES2311755T3 (es) * 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
MXPA06003749A (es) * 2003-10-03 2006-06-14 Pfizer Derivados de tropano.
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
DK1761542T3 (da) 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Hiv―1 감염 환자에서 바이러스 부하를 감소시키는방법
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2007144720A2 (en) * 2006-06-12 2007-12-21 Pfizer Products Inc. Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
US20080146605A1 (en) * 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
EP2456309B1 (en) * 2009-07-24 2015-12-23 GlaxoSmithKline LLC Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV.
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技(上海)有限公司 4,4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
EE03877B1 (et) * 1994-04-19 2002-10-15 Neurosearch A/S Tropaan-2-aldoksiimi derivaadid neurotransmitteritagasihaarde inhibiitoritena
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6281212B1 (en) * 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy

Also Published As

Publication number Publication date
CN1437599A (zh) 2003-08-20
JP4854970B2 (ja) 2012-01-18
EE200200656A (et) 2004-06-15
NO20025227L (no) 2002-10-31
CY2022009I1 (el) 2022-05-27
HUP0302474A3 (en) 2007-05-29
EA005382B1 (ru) 2005-02-24
RS51436B (sr) 2011-04-30
HK1054927A1 (en) 2003-12-19
NL300338I2 (nl) 2008-06-02
HRP20020938B1 (en) 2011-05-31
NO2010007I2 (no) 2013-09-09
EG24137A (en) 2008-08-06
KR100523501B1 (ko) 2005-10-25
CZ20023806A3 (cs) 2004-01-14
ME00555B (me) 2011-12-20
PA8517101A1 (es) 2002-10-24
HK1078573A1 (en) 2006-03-17
JP2005194283A (ja) 2005-07-21
AU2001252482C1 (en) 2001-12-03
NZ521477A (en) 2004-07-30
NO327892B1 (no) 2009-10-12
IS2511B (is) 2009-05-15
HRP20020938A2 (en) 2005-02-28
DE60102233T2 (de) 2005-01-27
DE122008000011I1 (de) 2008-06-05
EA007580B1 (ru) 2006-12-29
LU91417I9 (online.php) 2019-01-02
TR200400541T4 (tr) 2004-04-21
MXPA02011631A (es) 2003-03-27
ME00555A (en) 2011-12-20
DE60135685D1 (de) 2008-10-16
EA200401056A1 (ru) 2005-04-28
ES2215129T3 (es) 2004-10-01
GEP20063799B (en) 2006-04-25
BG65966B1 (bg) 2010-07-30
BR0110955A (pt) 2003-06-03
YU82202A (sh) 2005-11-28
DE60102233D1 (de) 2004-04-08
CN100355753C (zh) 2007-12-19
TNSN01077A1 (fr) 2005-11-10
EP1990341B1 (en) 2013-01-23
BRPI0110955B1 (pt) 2016-06-28
PL359267A1 (en) 2004-08-23
CN1279040C (zh) 2006-10-11
BG107140A (bg) 2003-05-30
WO2001090106A3 (en) 2002-03-28
CA2408909C (en) 2006-06-27
WO2001090106A2 (en) 2001-11-29
SI1284974T1 (en) 2004-08-31
EP1526134B1 (en) 2008-09-03
CN1680371A (zh) 2005-10-12
MY131019A (en) 2007-07-31
UY26727A1 (es) 2001-12-28
CY2008006I1 (el) 2009-11-04
ATE260914T1 (de) 2004-03-15
PT1526134E (pt) 2008-10-28
KR100548854B1 (ko) 2006-02-02
AP2002002663A0 (en) 2002-12-31
MA26902A1 (fr) 2004-12-20
NO2010007I1 (no) 2010-04-08
HK1090836A1 (en) 2007-01-05
OA12264A (en) 2003-11-10
NL300338I1 (nl) 2008-05-01
MY153023A (en) 2014-12-31
CY2008006I2 (el) 2009-11-04
JP3693957B2 (ja) 2005-09-14
DZ3464A1 (online.php) 2001-11-29
TWI230160B (en) 2005-04-01
EP1526134A3 (en) 2006-11-29
HU225810B1 (en) 2007-10-29
RS20090438A (sr) 2010-05-07
BRPI0110955B8 (pt) 2021-05-25
LTPA2008004I1 (lt) 2020-07-27
AP1965A (en) 2009-03-04
IL152531A0 (en) 2003-05-29
CZ299102B6 (cs) 2008-04-23
KR20030004417A (ko) 2003-01-14
LU91417I2 (fr) 2008-04-22
PE20011371A1 (es) 2002-01-18
CA2408909A1 (en) 2001-11-29
FR08C0007I2 (fr) 2009-01-15
EP1284974B1 (en) 2004-03-03
CR10145A (es) 2008-08-19
JP2003534343A (ja) 2003-11-18
EP1526134A2 (en) 2005-04-27
ATE407134T1 (de) 2008-09-15
IS6565A (is) 2002-09-24
FR08C0007I1 (online.php) 2008-04-25
ES2311126T3 (es) 2009-02-01
SI1526134T1 (sl) 2008-12-31
EA200201141A1 (ru) 2003-04-24
DK1284974T3 (da) 2004-06-07
SK16432002A3 (sk) 2004-01-08
HUP0302474A2 (hu) 2003-11-28
AU2001252482B2 (en) 2006-01-19
CY2022009I2 (el) 2022-05-27
PL200551B1 (pl) 2009-01-30
NO20025227D0 (no) 2002-10-31
AU5248201A (en) 2001-12-03
SK286129B6 (sk) 2008-04-07
IL152531A (en) 2010-05-17
KR20050046743A (ko) 2005-05-18
AR028622A1 (es) 2003-05-14
CY1108451T1 (el) 2014-04-09
DK1526134T3 (da) 2008-11-17
NO2020019I1 (no) 2020-06-30
ES2401812T3 (es) 2013-04-24
AR060159A2 (es) 2008-05-28
MY156920A (en) 2016-04-15
EP1284974A2 (en) 2003-02-26
EP1990341A1 (en) 2008-11-12
PT1284974E (pt) 2004-06-30
RS50904B (sr) 2010-08-31
LTC1284974I2 (lt) 2020-11-10
CU23288B7 (es) 2008-06-30

Similar Documents

Publication Publication Date Title
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
EE200200704A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
ZA200303794B (en) Heterocyclylalkyl piperidine derivatives, their preparation and compositions containing same.
HUP9802822A3 (en) Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients
AU2001241474A1 (en) Biosensor compositions and methods of use
IL154981A0 (en) Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
NO990685L (no) FremgangsmÕte ved inkubering av u°nsket smak i orale sammensetninger
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
AU2268401A (en) Novel succinate compounds, compositions and methods of use and preparation
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
EE04917B1 (et) Antihistamiinsed spirohendid, vahehendid ja farmatseutiline kompositsioon ning nende valmistamismeetodid ja kasutamine
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
WO2002041881A3 (de) Repinotan-kit
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
PL356911A1 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
AU2002218322A1 (en) Substituted cyclohexenes
AU4913399A (en) Thioazepinone derivatives, preparation method and intermediates therefor, use asmedicines and pharmaceutical compositions containing same
AU2002239739A1 (en) Compositions, methods and kits relating to remodelin

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

AA1Y Spc filed

Free format text: PRODUCT NAME: CELSENTRI-MARAVIROC

Spc suppl protection certif: C20090002

Filing date: 20090529

FG1Y Spc granted

Free format text: PRODUCT NAME: CELSENTRI-MARAVIROC

Spc suppl protection certif: C20090002 00023

Filing date: 20090529

Extension date: 20220918

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
SPCM Correction and amendment to the data concerning application for a supplementary protection certificate

Spc suppl protection certif: C20090002 00023

Extension date: 20220920

GB1A Change in the ownership or in the address of the owner
SPCZ Extension of supplementary protection certificate: granted [paediatric extension]

Free format text: PRODUCT NAME: MARAVIROC; NATIONAL AUTHORISATION NUMBER: EMA/253407/2017; DATE OF AUTHORISATION: 20170421

Spc suppl protection certif: C20090002

Extension date: 20230318